Portfolio company Karuna Therapeutics (NASDAQ: KRTX) was acquired by Bristol Myers Squibb.
Karuna Therapeutics is focused on developing first-in-class therapeutics for central nervous system disorders, particularly schizophrenia and Alzheimer's disease
Karuna Therapeutics is focused on developing first-in-class therapeutics for central nervous system disorders, particularly schizophrenia and Alzheimer's disease. Their lead product candidate, KarXT, targets muscarinic receptors to improve treatment outcomes for patients.